Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;16(4):437-43.
doi: 10.1128/CVI.00327-08. Epub 2008 Nov 19.

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains

György Fazekas  1 , Rita Martosne-Mendi, Istvan Jankovics, Istvan Szilvasy, Zoltan Vajo
Affiliations

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains

György Fazekas et al. Clin Vaccine Immunol. 2009 Apr.

Abstract

High fatality rates and multiple cases of transmission of avian H5N1 influenza viruses to humans illustrate the urgent need for an efficacious, cross-protective vaccine against H5N1 strains. Extensive genetic characterization of H5N1 strains has elucidated the natural evolutionary relationship of these strains, linking groups known as clades to a common ancestor. Although the clades and subclades probably differ sufficiently in their antigenic structure to warrant the preparation of different vaccines, there is some evidence that cross-reactive immunity can be afforded. We aimed to assess the immunogenicity of a clade 1 H5N1 (NIBRG-14) whole-virus vaccine with an aluminum phosphate adjuvant and to determine whether it can induce cross-reactive immunity against antigenically drifted clade 2 H5N1 strains, both those derived by reverse genetics and wild-type isolates. A total of 88 (44 adult and 44 elderly) subjects, who received one dose (6 microg) of the vaccine, were studied. As judged by U.S. and European licensing criteria based on hemagglutination inhibition, the subjects developed cross-reactive immunity against all studied H5N1 strains belonging to a clade different from that of the strain utilized to produce the vaccine. Our findings highlight the importance of stockpiling, since cross-immune reactions induced by prepandemic vaccines will likely reduce morbidity and mortality in case of a pandemic.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Evolution of the H5N1 hemagglutinin gene. The arrows indicate the vaccine strain (Vietnam/1194/2004) and the strains against which cross-reactive immunity was tested.
FIG. 2.
FIG. 2.
Seroconversion rates (percentages of subjects) for adult and elderly subjects by hemagglutination inhibition.
FIG. 3.
FIG. 3.
Postvaccination/prevaccination GMT ratios for adult and elderly subjects by hemagglutination inhibition.
FIG. 4.
FIG. 4.
Seropositivity rates (percentages of subjects) for adult and elderly subjects by hemagglutination inhibition.
FIG. 5.
FIG. 5.
Seroconversion rates (percentages of subjects) for adult and elderly subjects by microneutralization.
FIG. 6.
FIG. 6.
Postvaccination/prevaccination GMT ratios for adult and elderly subjects by microneutralization.
FIG. 7.
FIG. 7.
Total antibody levels measured by ELISA. The difference between the titers for NIBRG-14 on day 21 and day 0 was taken as 100% for purposes of comparison.
See this image and copyright information in PMC

References

    1. Carrat, F., and A. Flahault. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 256852-6862. - PubMed
    1. Committee for Proprietary Medicinal Products. 5 April 2004. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. CPMP/VEG/4717/03. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
    1. Committee for Proprietary Medicinal Products. 12 March 1997. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. European Agency for the Evaluation of Medicinal Products, London, United Kingdom. http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf.
    1. European Centre for Disease Prevention and Control. March 2007. Technical report. Expert advisory groups on human H5N1 vaccines. Scientific questions. European Centre for Disease Prevention and Control, Stockholm, Sweden. http://ecdc.europa.eu/documents/pdf/Sci%20Questions%20final.pdf.
    1. European Directorate for the Quality of Medicines & HealthCare. July 2007. European pharmacopeia, 5th ed., supplement 5.8, p. 3406-3407. CD-ROM. European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France.

MeSH terms